# Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure

> **NIH NIH R01** · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $644,275

## Abstract

Plasmodium vivax threatens half of the world’s population. While on-going malaria elimination efforts are
successfully reducing the burden of falciparum malaria worldwide, the situation is much less promising for P.
vivax. In particular, the unique ability of P. vivax parasites to remain dormant in the liver and cause relapse
infections weeks or months later greatly complicates malaria elimination campaigns. Here we propose to conduct
a tightly-controlled field study in Cambodia, specifically designed to support and empower state-of-the-art
genomic analyses, to determine the frequency of relapse and the factors associated with hypnozoite reactivation,
as well as to rigorously evaluate the efficacy of different doses of primaquine for radical cure treatment. Our
studies will provide a unique perspective on P. vivax relapse and will contribute to better understand how to
successfully eliminate this understudied parasite.

## Key facts

- **NIH application ID:** 10469663
- **Project number:** 5R01AI146590-03
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** David Serre
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $644,275
- **Award type:** 5
- **Project period:** 2020-07-17 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469663

## Citation

> US National Institutes of Health, RePORTER application 10469663, Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure (5R01AI146590-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10469663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*